Hyperuricemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hyperuricemia Market Outlook

Thelansis’s “Hyperuricemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperuricemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hyperuricemia Overview

Hyperuricemia refers to an elevated concentration of uric acid in the bloodstream, with levels surpassing the standard upper limit of 6.8mg/dL. When uric acid content reaches 7 mg/dL or more, it is considered to be saturated, and this can lead to the emergence of symptoms. This elevation in uric acid arises from an excess production of uric acid, a reduced ability to eliminate uric acid or a combination of these two processes. The elevated uric acid levels can also be observed in conditions involving rapid breakdown of cells, such as hemolysis, rhabdomyolysis, and tumor lysis, which lead to accelerated purine degradation. Additionally, reduced excretion of uric acid can result from issues like renal insufficiency and metabolic acidosis. Hyperuricemia is linked to the development of gout, a condition characterized by the accumulation of uric acid in the blood and tissues, as well as nephrolithiasis (formation of kidney stones).

Urate Overproduction:

1. Consumption of diets rich in purines
2. Disorders in purine metabolism, such as hypoxanthine phosphoribosyltransferase (HPRT) deficiency and overactivity of phosphoribosylpyrophosphate (PRPP) synthetase
3. Cellular breakdown or turnover in conditions like lymphoproliferative diseases, myeloproliferative disease, polycythemia vera, Paget disease, psoriasis, tumor lysis, hemolysis, rhabdomyolysis, and during exercise

Decreased Uric Acid Excretion:

1. Acute or chronic kidney disease
2. Acidosis (lactic acidosis, ketoacidosis)
3. Dehydration
4. Medications or toxins (diuretics, niacin, pyrazinamide, ethambutol, cyclosporin, beryllium, salicylates, lead, alcohol)
5. Conditions like sarcoidosis, hyperparathyroidism, hypothyroidism, Bartter syndrome, and Down syndrome

Gout, characterized by an accumulation of uric acid leading to the formation of urate monohydrate crystals within joints, is a metabolic disorder. Crystallization is facilitated in acidic and cold environments, causing more crystals to form in peripheral joints like the big toe. Gout predominantly affects males, with a male-to-female ratio of 4:1. Elevated uric acid levels can precede the clinical onset of gout by a decade or more. Many individuals with hyperuricemia remain symptom-free and do not require medical intervention, as they may never experience gout or nephrolithiasis. Medication's potential drawbacks and expenses often outweigh the benefits for these asymptomatic cases. Urate-lowering drugs (such as Allopurinol, Probenecid, and Rasburicase) are only recommended for asymptomatic patients undergoing cytolytic therapy for malignancies, aiming to prevent tumor lysis syndrome.

• In the United States, hyperuricemia has been observed in 14.6% of the population, which accounts for an estimated 32.5 million individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: